文献速递胸部肿瘤

非小细胞肺癌中高水平ERBB2扩增的患病率与治疗靶向

Prevalence and Therapeutic Targeting of High-Level ERBB2 Amplification in NSCLC.
PubMed 文献 · J Thorac Oncol · 2023-12-26

研究基于5769例非小细胞肺癌样本的机构内二代测序数据,评估高水平ERBB2扩增(≥6拷贝)的临床病理与基因组特征,并在临床前模型和患者中探索HER2抗体药物偶联物治疗策略。高水平ERBB2扩增见于0.9%的肺腺癌,可可靠预测HER2过表达,曲妥珠单抗德鲁替康在体外和体内临床前模型中有效,并报告两例抗HER2抗体药物偶联物临床活性。

要点

  • 高水平ERBB2扩增见于0.9%的肺腺癌,可可靠预测HER2过表达。
  • ERBB2扩增见于两种不同临床病理与基因组亚群:吸烟史患者中作为唯一促分裂驱动,或轻/从不吸烟患者中与其他驱动共存。
  • 曲妥珠单抗德鲁替康在携带ERBB2扩增的非小细胞肺癌体外和体内临床前模型中有效。

核心结论

  • 高水平ERBB2扩增可可靠预测非小细胞肺癌患者的HER2过表达,HER2抗体药物偶联物是该人群的有效治疗。

研究设计与样本

  • 研究查询机构内二代DNA测序数据(OncoPanel),来自5769例非小细胞肺癌样本(5075例患者),筛选高水平ERBB2扩增(≥6拷贝)病例,并从电子病历提取临床和人口学特征。
  • 在非小细胞肺癌临床前模型和携带ERBB2扩增的患者中评估泛ERBB抑制剂阿法替尼或HER2抗体药物偶联物(曲妥珠单抗德鲁替康和曲妥珠单抗美坦新)的疗效。

主要发现

  • 高水平ERBB2扩增见于0.9%的肺腺癌,并可靠预测HER2过表达。
  • ERBB2扩增事件见于两种不同的非小细胞肺癌临床病理和基因组亚群:在有吸烟史患者肿瘤中作为唯一促分裂驱动,或在轻或从不吸烟史患者中作为与其他促分裂驱动的伴随改变。
  • 曲妥珠单抗德鲁替康在携带ERBB2扩增的非小细胞肺癌体外和体内临床前模型中显示有效治疗。
  • 报告两例患者在先前靶向治疗后获得ERBB2扩增,接受抗HER2抗体药物偶联物治疗显示临床活性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: ERBB2 amplification in lung cancer remains poorly characterized. HER2 (encoded by ERBB2) is a transmembrane tyrosine kinase capable of ligand-independent dimerization and signaling when overexpressed, and a common cause of HER2 overexpression is ERBB2 amplification. Here, we evaluated the clinicopathologic and genomic characteristics of ERBB2-amplified NSCLC and explored a HER2 antibody-drug conjugate (ADC) therapeutic strategy. METHODS: Our institutional next-generation DNA sequencing data (OncoPanel) from 5769 NSCLC samples (5075 patients) were queried for cases having high-level ERBB2 amplification (≥6 copies). Clinical and demographic characteristics were extracted from the electronic medical records. Efficacy of the pan-ERBB inhibitor afatinib or HER2 ADCs (trastuzumab deruxtecan and trastuzumab emtansine) was evaluated in NSCLC preclinical models and patients with ERBB2 amplification. RESULTS: High-level ERBB2 amplification was identified in 0.9% of lung adenocarcinomas and reliably predicted overexpression of HER2. ERBB2 amplification events are detected in two distinct clinicopathologic and genomic subsets of NSCLC: as the sole mitogenic driver in tumors arising in patients with a smoking history or as a concomitant alteration with other mitogenic drivers in patients with a light or never smoking history. We further reveal that trastuzumab deruxtecan is effective therapy in in vitro and in vivo preclinical models of NSCLC harboring ERBB2 amplification and report two cases of clinical activity of an anti-HER2 ADC in patients who acquired ERBB2 amplification after previous targeted therapy. CONCLUSIONS: High-level ERBB2 amplification reliably predicts HER2 overexpression in patients with NSCLC, and HER2 ADC is effective therapy in this population.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Odintsov I, Makarem M, Nishino M, et al. Prevalence and Therapeutic Targeting of High-Level ERBB2 Amplification in NSCLC. J Thorac Oncol. 2023. PMID: 38154514. doi:10.1016/j.jtho.2023.12.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。